Advertisement


Tony Mok, MD, on NSCLC: Targeted Treatment Update

ESMO 2018 Congress

Advertisement

Tony Mok, MD, of the Chinese University of Hong Kong, discusses two important studies in non–small cell lung cancer: FLAURA, which looked at the first-line activity of osimertinib and the mechanisms of resistance; and ALESIA, which examined crizotinib dosing.  



Related Videos

Breast Cancer

Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Research Highlights

Sibylle Lobil, MD, PhD, of the German Breast Group, discusses findings in metastatic breast cancer from the IMpassion130 trial in triple-negative disease and from the PALOMA3 and S...

Lung Cancer
Immunotherapy

Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy and Targeted Treatments

Johan F. Vansteenkiste, MD, PhD, of Catholic University Leuven, summarizes a session he co-chaired that included discussion of translating advances in stage IV disease to nonmetast...

Skin Cancer
Immunotherapy

Jeffrey S. Weber, MD, PhD, on Discontinuing Immunotherapy: When Is the Right Time?

Jeffrey S. Weber, MD, PhD, of the NYU Langone Perlmutter Cancer Center, discusses how long people with melanoma should be treated with PD-1 blockade and the data on remission rates...

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on Immunotherapy for Thoracic Malignancies: Expert Perspective

Martin Reck, MD, PhD, of the LungenClinic, discusses recent updates on biomarkers beyond PD-L1 expression; mechanisms and management of resistance; as well as combinations an...

Skin Cancer
Immunotherapy

Caroline Robert, MD, PhD, on Advanced Melanoma: Research Highlights

Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses two high-impact studies in stage III melanoma treatment: an update of the COMBI-AD trial examining dabrafenib a...

Advertisement

Advertisement



;
Advertisement